Acquisition by Dennis Lanfear of 375000 shares of Coherus BioSciences at 0.9462 subject to Rule 16b-3
| CHRS Stock | USD 0.91 0.04 4.60% |
Slightly above 55% of Coherus BioSciences' private investors are presently thinking to get in. The analysis of overall sentiment of trading Coherus BioSciences stock suggests that some investors are interested at this time. Coherus BioSciences' investing sentiment can be driven by a variety of factors including economic data, Coherus BioSciences' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Coherus BioSciences Director, Officer: President & Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Coherus BioSciences Fundamental Analysis
We analyze Coherus BioSciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Coherus BioSciences is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Coherus BioSciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Coherus BioSciences stock to make a market-neutral strategy. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics with similar companies.
Peers
Coherus BioSciences Related Equities
| NUVB | Nuvation Bio | 3.59 | ||||
| MGNX | MacroGenics | 3.05 | ||||
| FGEN | FibroGen | 0.58 | ||||
| CTMX | CytomX Therapeutics | 0.84 | ||||
| ATRA | Atara Biotherapeutics | 0.88 | ||||
| LYRA | Lyra Therapeutics | 1.17 | ||||
| ASMB | Assembly Biosciences | 2.78 |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.